For us to trust it on certain subjects, researchers in the growing field of interpretability might need to learn how to open the black box of its brain.

Acre Therapeutics is a winner of the 2025 NIA Start-Up Challenge, and was awarded $65,000 by the National Institute on Aging.

Our genomes are peppered with DNA segments called retrotransposons that can move from place to place. When unleashed, some can kill nerves and promote inflammation — a discovery that may inspire treatments for neurodegeneration.

The 2025 Roger Ackerman Memorial Grant will fund Cheung’s research toward developing an RNA-based therapy for Alzheimer’s disease.

The work of Bess Frost, the Salame-Feraud Director of the Center for Alzheimer's Disease Research, and John Sedivy, director of the Center on the Biology of Aging, is highlighted in this Science article on retrotransposon research.

On September 23, Edward “Ted” Huey, M.D., joined some of the nation’s leading experts on Alzheimer’s disease at the National Institute on Aging to help set research priorities and to present his work. Huey’s main message: Memory loss is not the only sign of this common and devastating disease.

Alzheimer’s and related dementias also cause motor symptoms, like hand tremors or weakness. And there can be neuropsychiatric symptoms: angry outbursts, sudden apathy, even visual hallucinations. Loss of appetite and weight loss and trouble getting to sleep or staying asleep are also common signs of Alzheimer’s and other common forms of dementia, which afflict more than 6 million people in the United States – including 40% of people over the age of 85, according to federal statistics.

Edward “Ted” Huey, the director of the Memory and Aging Program at Butler Hospital and a professor of psychiatry and human behavior at Brown University, has been named the associate director of Brown University's Center for Alzheimer's Disease Research.